The journal brings together articles on a range of oncology specialties, covering cancer biology, clinical cancer research and cancer prevention, with authors from across the globe.
Below are some top articles which Editor-in-Chief Prof. Qingyi Wei has highlighted from the issue. We hope that you enjoy this exciting new content.
Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer
Anne-Sophie Chretien, Alexandre Harlé, Magali Meyer-Lefebvre, Marie Rouyer, Marie Husson, Carole Ramacci, Valentin Harter, Pascal Genin, Agnès Leroux and Jean-Louis Merlin
Summary: We performed our study with three techniques (TaqMan, HRM and PCR-RFLP) on 674 paraffin embedded tumors specimens and processed retrospectively discrepancies with a fourth one (CE-IVD COBAS 4800 KRAS mutation test).The main finding of this study is to propose a routine scheme for the determination of KRAS mutations in colorectal cancers ensuring high specificity and appropriate delay for first line prescription of anti-EGFR antibodies.
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases
Heike Niessner, Andrea Forschner, Bernhard Klumpp, Jürgen B. Honegger, Maria Witte, Antje Bornemann, Reinhard Dummer, Annemarie Adam, Jürgen Bauer, Ghazaleh Tabatabai, Keith Flaherty, Tobias Sinnberg, Daniela Beck, Ulrike Leiter, Cornelia Mauch, Alexander Roesch, Benjamin Weide, Thomas Eigentler, Dirk Schadendorf, Claus Garbe, Dagmar Kulms, Leticia Quintanilla-Martinez and Friedegund Meier
Summary: In patients with metastatic melanoma, brain metastases are the most common cause of death. Our findings suggest that hyperactivation of the AKT survival pathway in melanoma brain metastases promotes the survival and drug resistance of melanoma cells in the brain parenchyma. Inhibition of this pathway thus has potential as a novel strategy for the treatment of melanoma brain metastases.
A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma
Akihiko Osaki, Takeshi Suda, Kenya Kamimura, Atsunori Tsuchiya, Yasushi Tamura, Masaaki Takamura, Masato Igarashi, Hirokazu Kawai, Satoshi Yamagiwa and Yutaka Aoyagi
Summary: An excess dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma may enhance rapid tumor growth in case of resistance to cisplatin. A relationship between cisplatin dose and a tumor growth rate suggests that cisplatin (mg) should not be applied more than creatinine clearance (mL/min/1.73 m2) especially when it is not clear whether a target of HCC is sensitive or resistant to cisplatin, and the targeted liver volume should be smaller than 200 times of the CDDP dose (mg).
Cancer Medicine is a peer reviewed, interdisciplinary journal providing rapid publication of cutting-edge research from global biomedical researchers across the cancer sciences.